Skip to main content
SpringerLink
Log in

Measuring Direct Oral Anticoagulants

  • Protocol
  • First Online:
Hemostasis and Thrombosis

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1646))

Abstract

Direct oral anticoagulants (DOACs) can be quantified using methods that can be performed in any clinical or research laboratory using manual or automated instrument platforms. Dabigatran etexilate, the oral direct thrombin inhibitor, can be quantified by drug-calibrated clot or chromogenic-based assays using either thrombin or ecarin as substrates. Oral direct anti-Xa inhibitors, such as rivaroxaban, apixaban, and edoxaban, can be quantified with drug-calibrated anti-Xa kits or reagents as typically used for measuring heparins (unfractionated, low molecular weight, or pentasaccharides).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Cruickshank MK, Levine MN, Hirsh J, Roberts R, Siguenza M (1991) A standard heparin nomogram for the management of heparin therapy. Arch Intern Med 151:333–337

    Article  CAS  PubMed  Google Scholar 

  2. Brill-Edwards P, Ginsberg JS, Johnston M, Hirsh J (1993) Establishing a therapeutic range for heparin therapy. Ann Intern Med 119:104–109

    Article  CAS  PubMed  Google Scholar 

  3. Peterson CE, Kwaan HC (1986) Current concepts of warfarin therapy. Arch Intern Med 146:581–584

    Article  CAS  PubMed  Google Scholar 

  4. Poller L (1988) A simple nomogram for the derivation of international normalized ratios for the standardisation of prothrombin times. Thromb Haemost 30:18–20

    Google Scholar 

  5. Planes A, Vochelle N, Mazas F, Mansat C, Zucman J, Landais A, Pascariello JC, Weill D, Butel J (1988) Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. Thromb Haemost 22:407–410

    Google Scholar 

  6. Wells PS, Kovacs MJ, Bormanis J, Forgie MA, Goudie D, Morrow B, Kovacs J (1998) Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin: a comparison of patient self-injection with homecare injection. Arch Intern Med 14:1809–1812

    Article  Google Scholar 

  7. Ieko M, Naitoh S, Yoshida M, Takahashi N (2016) Profiles of direct oral anticoagulants and clinical usage-dosage and dose regimen differences. J Intensive Care 10(4):19

    Article  Google Scholar 

  8. Nutescu EA, Burnett A, Fanikos J, Spinler S, Wittkowsky A (2016) Pharmacology of anticoagulants used in the treatment of venous thromboembolism. J Thromb Thrombolysis 41:15–31. Erratum in: J Thromb Thrombolysis (2016) 42:296–311

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Lippi G, Favalaro EJ (2015) Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants(DOACs): is there consensus? Clin Chem Lab Med 53:185–197

    CAS  PubMed  Google Scholar 

  10. Love JE, Ferrell C, Chandler WL (2007) Monitoring direct thrombin inhibitors with a plasma diluted thrombin time. Thromb Haemost 98:234–242

    CAS  PubMed  Google Scholar 

  11. Stangier J, Wetzel K, Wienen W et al (2009) Measurement of the pharmacodynamic effect of dabigatran etexilate: thrombin clotting time (abstract PP-TH-134). J Thromb Haemost 7(Suppl 2):978

    Google Scholar 

  12. Hapgood G, Butler J, Malan E, Chunilal S, Tran H (2013) The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples. Thromb Haemost 110:308–315

    Article  CAS  PubMed  Google Scholar 

  13. Douxfils J, Lessire S, Dincq AS, Hjemdahl P, Rönquist-Nii Y, Pohanka A, Gourdin M, Chatelain B, Dogné JM, Mullier F (2015) Estimation of dabigatran plasma concentrations in the perioperative setting. An ex vivo study using dedicated coagulation assays. Thromb Haemost 113:862–869

    Google Scholar 

  14. Spannagl M, Bichler J, Birg A, Lill H, Schramm W (1991) Development of a chromogenic substrate assay for the determination of hirudin in plasma. Blood Coagul Fibrinolysis 2:121–127

    Article  CAS  PubMed  Google Scholar 

  15. Hafner G, Fickenscher K, Friesen HJ, Rupprecht HJ, Konheiser U, Ehrenthal W, Lotz J, Prellwitz W (1995) Evaluation of an automated chromogenic substrate assay for the rapid determination of hirudin in plasma. Thromb Res 15:165–173

    Article  Google Scholar 

  16. Pötzsch B, Hund S, Madlener K, Unkrig C, Müller-Berghaus G (1997) Monitoring of recombinant hirudin: assessment of a plasma-based ecarin clotting time assay. Thromb Res 86:373–383

    Article  PubMed  Google Scholar 

  17. Nowak G (2003) The ecarin clotting time, a universal method to quantify direct thrombin inhibitors. Pathophysiol Haemost Thromb 33:173–183

    Article  CAS  Google Scholar 

  18. Lindhoff-Last E, Piechottka GP, Rabe F, Bauersachs R (2000) Hirudin determination in plasma can be strongly influenced by the prothrombin level. Thromb Res 100:55–60

    Article  CAS  PubMed  Google Scholar 

  19. Stocker K, Fischer H, Brogli M (1986) Chromogenic assay for the prothrombin activator ecarin from the venom of the saw-scaled viper (Echis carinatus). Toxicon 24:81–89

    Article  CAS  PubMed  Google Scholar 

  20. Spannagl M, Bichler J, Birg A, Lill H, Schramm W (1991) Development of a chromogenic substrate assay for the determination of hirudin in plasma. Blood Coagul Fibrinolysis 2:121–127

    Article  CAS  PubMed  Google Scholar 

  21. Lange U, Nowak G, Bucha E (2003) Ecarin chromogenic assay--a new method for quantitative determination of direct thrombin inhibitors like hirudin. Pathophysiol Haemost Thromb 33:184–191

    Article  CAS  Google Scholar 

  22. Gosselin RC, Dwyre DM, Dager WE (2013) Measuring dabigatran concentrations using a chromogenic ecarin clotting time assay. Ann Pharmacother 47:1635–1640

    Article  CAS  PubMed  Google Scholar 

  23. Purified bovine factor Xa package insert. Hyphen BioMed, Neuville-Sur-Oise, France. Revision 12–2016

    Google Scholar 

  24. Harenberg J, Krämer R, Giese C, Marx S, Weiss C, Wehling M (2011) Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability. J Thromb Thrombolysis 32:267–271

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Wong PC, Crain EJ, Xin B, Wexler RR, Lam PY, Pinto DJ, Luettgen JM, Knabb RM (2008) Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost 6:820–829

    Google Scholar 

  26. Sato K, Taniuchi Y, Kawasaki T, Hirayama F, Koshio H, Matsumoto Y (1998) Relationship between the antithrombotic effect of YM-75466, a novel factor Xa inhibitor, and coagulation parameters in rats. Eur J Pharmacol 347:231–236

    Article  CAS  PubMed  Google Scholar 

  27. Honda Y, Kamisato C, Morishima Y (2016) Edoxaban, a direct factor Xa inhibitor, suppresses tissue-factor induced human platelet aggregation and clot-bound factor Xa in vitro: comparison with an antithrombin-dependent factor Xa inhibitor, fondaparinux. Thromb Res 141:17–21

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology and Laboratory Medicine, Davis Health System, University of California, 4400 V Street, Sacramento, CA, 95817, USA

    Robert C. Gosselin

  2. Department of Pharmacy, Namur Thrombosis and Hemostasis Center, Namur Research Institute for Life Sciences, University of Namur, Namur, Belgium

    Jonathan Douxfils

Authors
  1. Robert C. Gosselin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jonathan Douxfils
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert C. Gosselin .

Editor information

Editors and Affiliations

  1. Department of Haematology, Sydney Centres for Thrombosis and Haemostasis, Institute of Clinical Pathology and Medical Research (ICPMR), NSW Health Pathology, Westmead Hospital, Westmead, New South Wales, Australia

    Emmanuel J. Favaloro

  2. Section of Clinical Biochemistry, University of Verona, Verona, Italy

    Giuseppe Lippi

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Science+Business Media LLC

About this protocol

Cite this protocol

Gosselin, R.C., Douxfils, J. (2017). Measuring Direct Oral Anticoagulants. In: Favaloro, E., Lippi, G. (eds) Hemostasis and Thrombosis. Methods in Molecular Biology, vol 1646. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7196-1_18

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-7196-1_18

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-7194-7

  • Online ISBN: 978-1-4939-7196-1

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation